Nanoparticle-Based Drug Delivery Systems for Cancer Therapy

Dear Colleagues,

Despite considerable advances in oncology, conventional chemotherapy continues to face significant challenges, such as nonspecific biodistribution, severe systemic toxicity, and the emergence of multidrug resistance. In response, the field of nanoparticle-based drug delivery has rapidly evolved, offering transformative potential to enhance drug stability and bioavailability, improve tumor-specific targeting through both passive and active strategies, and achieve controlled release of therapeutic agents directly within the tumor microenvironment.

This Special Issue, “Nanoparticle-Based Drug Delivery Systems for Cancer Therapy,” is dedicated to showcasing cutting-edge research that bridges material science, pharmaceutical engineering, and oncology. We aim to compile a comprehensive collection of works that highlight the rational design of novel nanocarriers, sophisticated targeting and controlled release mechanisms, and the engineering of intelligent, stimuli-responsive systems. We welcome studies that not only demonstrate innovative synthesis and functionalization approaches but also rigorously evaluate biological interactions and therapeutic outcomes in relevant models.

Key topics of interest include the design and synthesis of novel nanocarriers from advanced biomaterials; targeted delivery and controlled release strategies informed by engineering principles; engineering of multifunctional and stimuli-responsive nanosystems; biocompatibility, biodegradation kinetics, and long-term toxicity assessment; integrated engineering technologies for combination therapy and theranostics; preclinical and clinical translation of nanomedicines; scalable manufacturing and quality control of biomaterial-based therapeutics; and computational modeling and AI-assisted design for optimizing material and kinetic properties.

We believe that this collection will serve as a valuable platform for disseminating breakthroughs and inspiring further innovations aimed at overcoming biological barriers and accelerating the clinical adoption of next-generation nanotherapeutics.

Prof. Dr. Tianzhu Zhang
Dr. Qiaoyu Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.